Piramal Pharma invests over Rs 69 crore to expand its API capability
Read Also: Piramal partner Slate Run Pharma launches Cinacalcet Hydrochloride tablets in US
Piramal Pharma Solutions Chief Executive Officer Vivek Sharma said: "We are one of only a few companies in the contract development and manufacturing market that have the capability to produce HPAPIs at such low OELs."
The expansion enhances the company's ability to serve the growing antibody-drug conjugate market, the statement said.
Read Also: Panacea Biotec Bail out: Piramal, Bain offer Rs 992 crore deal
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at email@example.com. Check out more about our bureau/team here